Indian Development News 🇮🇳
Sun Pharma set to acquire US-based Organon in India's biggest Pharma cross-border M&A deal. #Medicine
Gujarat Themis Biosyn (GTBL) will acquire Japanese CDMO MicroBiopharm Japan for ₹1,300 cr via debt + equity, using a Japan SPV.
MBJ has 3 facilities, FY26 revenue ~₹570 cr, and expertise in microbial fermentation, biologics, ADCs, plasmids, and oncology APIs.
This follows GTBL’s ₹1,700 cr buy of Sanofi’s anti-infectives/TB portfolio last month. In Q3 FY26, GTBL posted ₹43.4 cr revenue, ₹12.5 cr profit. #Medicine #Biopharam
[Source]
MBJ has 3 facilities, FY26 revenue ~₹570 cr, and expertise in microbial fermentation, biologics, ADCs, plasmids, and oncology APIs.
This follows GTBL’s ₹1,700 cr buy of Sanofi’s anti-infectives/TB portfolio last month. In Q3 FY26, GTBL posted ₹43.4 cr revenue, ₹12.5 cr profit. #Medicine #Biopharam
[Source]
ETPharma.com
Gujarat Themis Biosyn to acquire Japanese CDMO MicroBiopharm for ₹1300 cr
Gujarat Themis Biosyn Limited has signed a ₹1300 crore deal to acquire MicroBiopharm Japan, enhancing its global manufacturing capabilities in pharmaceuticals, particularly in oncology and biologics. The acquisition is strategically aimed at expanding GTBL's…
❤37🔥1
Indian Development News 🇮🇳
Gujarat Themis Biosyn (GTBL) will acquire Japanese CDMO MicroBiopharm Japan for ₹1,300 cr via debt + equity, using a Japan SPV. MBJ has 3 facilities, FY26 revenue ~₹570 cr, and expertise in microbial fermentation, biologics, ADCs, plasmids, and oncology…
Gujarat Themis Biosyn Limited completed the 100% acquisition of MicroBiopharm Japan for JPY 21.5 billion, gaining advanced capabilities in oncology APIs, plasmid DNA, peptides, advanced biologics, and antibody-drug conjugate (ADC) conjugation. #Medicine #BioPharam
🔥40❤7👍5👏3